Atypical Stevens-Johnson syndrome caused by pembrolizumab in the treatment of metastatic melanoma - Are corticosteroids a safe treatment option?
Pembrolizumab is a humanized monoclonal antibody that targets programmed cell death receptor-1. Stevens-Johnson syndrome (SJS) secondary to pembrolizumab has rarely been described in the treatment of malignant melanoma (MM). A 62-year-old woman developed a widespread bullous eruption following admin...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
Wolters Kluwer Medknow Publications,
2020-01-01T00:00:00Z.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sailkapena: |
A1234.567 |
|---|---|
| Alea 1 | Eskuragarri |